Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXPO trial of injectable depot buprenorphine versus standard oral opioid agonist treatment for opioid use disorder
2018-004460-63Phase 3Unknown
- Sponsor
- South London and Maudsley NHS Foundation Trust
- Start
- Mar 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of buprenorphine, methadone, buprenorphine + naloxone and Espranor in opioid use disorder (OUD) (2 arms), sponsored by South London and Maudsley NHS Foundation Trust. Primary endpoint: Count of days abstinent from illicit/non-medical opioids during weeks 2 to 24. Status: unknown.
02
Drugs
buprenorphinemethadonebuprenorphine + naloxoneEspranor
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on 2018-004460-63.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004460-63.